NEWARK, Del, July 26, 2023 (GLOBE NEWSWIRE) -- Future Market Insights' latest Global Breast Cancer Screening Tests Market study reveals promising growth prospects. Factors such as an aging population, lifestyle changes, and government initiatives promoting early detection are driving this growth. With a current value of US$ 1.9 Billion in 2022, the market is expected to soar in the coming years. Governments worldwide are actively promoting early screening initiatives to combat breast cancer effectively.
The global market for breast cancer screening tests is projected to experience significant growth. By 2033, the market is anticipated to be worth US$ 4.4 Billion, growing at a CAGR of 7.8%. With a value share of approximately 54.3% in 2022, the imaging tests segment led the global market for breast cancer screening tests.
Globally, digital mammography has supplanted traditional film-based mammography. Digital mammography has advantages such as improved image quality, quicker image storage and retrieval, and the possibility of computer-aided detection (CAD) systems assisting radiologists in interpretation.
Imaging technologies, such as 3D mammography (tomosynthesis), have advanced in the breast cancer screening test market, providing more comprehensive images and reducing false-positive findings. Other developing technologies are being investigated for improved accuracy and patient experience, such as contrast-enhanced mammography and automated breast ultrasonography.
Stay Informed With The Latest Trends, Projections, And Advancements In Breast Cancer Screening Technologies, Helping You Make Informed Decisions In This Critical Healthcare Sector. Get Our Sample Report Now! https://www.futuremarketinsights.com/reports/sample/rep-gb-17758
Biomarker testing, in addition to imaging-based screening assays, is significant in breast cancer screening. Biomarkers, such as BRCA gene mutations and specific protein markers (e.g., HER2, hormone receptors), aid in determining a person's risk of getting breast cancer and guiding treatment recommendations.
Regulatory agencies, such as the United States Food and Drug Administration (FDA), are critical in authorizing and regulating breast cancer screening tests to assure their safety and efficacy. Compliance with regulatory regulations is required for screening test market entry and commercialization.
Key Takeaways from Breast Cancer Screening Tests Market:
- Among diagnostic test types, imaging tests account for US$ 1.1 billion in 2022, owing to their potential for computer-aided detection (CAD) systems to assist radiologists in interpretation.
- Hospitals held more than 42.3% of the global market share in 2022. This can be attributed to the fact that the majority of the world's population suffers from diseases that, with skilled assistance, can be appropriately detected in the hospital setting.
- By region, North American Breast Cancer Screening Tests Market held the dominant share in the world in 2022. The U.S. leads in this region with a high prevalence of breast cancer and a high requirement for breast cancer screening devices.
- East Asia is set to provide lucrative opportunities for players while growing at an expected growth rate of 10.5% CAGR over the forecast period.
“The growing cancer burden and increasing adoption of non-invasive treatment contribute to higher demand of breast cancer screening tests.” says an analyst of Future Market Insights.
Announces New Strategies to Thrive in Intense Market Competition:
The breast cancer screening test market is highly competitive, with key players including Ion Beam and Sumitomo Heavy Industries. These companies are constantly participating in partnerships, award competition with their products, and launching new products to gain a larger market share, focusing on affordability, convenience, and effectiveness.
- In June 2023, Heligenics, a cutting-edge biotech startup, announced the development of the first precise genetic test for choosing among breast cancer medicines.
- AstraZeneca
- Novartis
- Sanofi
- Pfizer
- Bayer AG
- GlaxoSmithKline plc
- Siemens Healthineers
- Hologic Inc.
- General Electric Company
- Koninklijke Philips NV
- Fujifilm Holdings
- A&G Pharmaceutical, Inc.
- Biocrates Life Sciences AG
- Metabolomic Technologies, Inc.
- Myriad Genetics
- OncoCyte Corporation
- POC Medical Systems, Inc.
- Hologic, Inc.
- Provista Diagnostics, Inc.
- BioTime, Inc.
To Acess the secrets of the Competition Dashboard and delve into the mystical realm of Branding and Promotional Strategies. Purchase now to harness unparalleled strategic insights! https://www.futuremarketinsights.com/checkout/17758
Global Breast Cancer Screening Tests Market: Historical Analysis and Projections for 2023-2033
Future Market Insights offers a unique perspective and actionable insights on the breast cancer screening tests market in its latest study, presenting a historical demand assessment of 2017 – 2022 and projections for 2023 – 2033. The global breast cancer screening tests market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader
The analysis is based on diagnostic test type (blood marker tests, imaging tests (mammography, MRI screening test, molecular breast imaging test, PET scan, ultrasound), genetic test (Fluorescence In Situ Hybridization and HER gene test), and immunohistochemistry tests), and end-user (hospitals, diagnostics centres, cancer institutes, research laboratories), across seven key regions around the world.
Key Market Segments Covered in the Breast Cancer Screening Test Industry Research:
By Diagnostics Test Type:
- Blood Marker Tests
- Imaging Test
- Mammography
- MRI screening test
- Molecular Breast Imaging Test
- PET scan
- Ultrasound
- Genetic Test
- Fluorescence In Situ Hybridization
- HER gene test
- Immunohistochemistry Test
By End User:
- Hospitals
- Diagnostic Centres
- Cancer Institutes
- Research Laboratories
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa
Covering Every Aspect Of The Market. The Report Provides Detailed Segmentation. To Customize your report connect with our Research Analyst and avail of the special discount! https://www.futuremarketinsights.com/customization-available/rep-gb-17758
Explore FMI’s Extensive ongoing Coverage in Healthcare Domain:
Breast Cancer Drug Market Size: The global breast cancer drug market size is expected to be valued at US$ 10,733.1 million in 2023. The increasing prevalence of the disease, along with evolving novel therapies, are some of the key factors likely to drive the market.
ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Share: The global ESR1 mutated metastatic breast cancer diagnostics market garnered a market value of US$ 58.70 Million in 2022 and is expected to accumulate a market value of US$ 185 Million by registering a CAGR of 11% in the forecast period 2023 to 2033.
Breast Biopsy Market Growth: The current estimated value of the breast biopsy market is US$ 2146.54 million in 2022. By 2032, the breast biopsy market is anticipated to grow at a 5.3% CAGR and reach a value of US$ 3,596.7 million.
Breast Biopsy Devices Market Trend: Global demand for the breast biopsy devices market is set to display growth at a CAGR of about 5.5% from 2022 to 2032, with an estimated market valuation to be around US$ 2.1 Billion as of 2022.
Breastfeeding Accessories Market Forecast: The global breastfeeding accessories market is projected to have a rapid-paced CAGR of 6.45% during the forecast period. The current valuation of the market is US$ 2.36 Billion in 2022.
Breast Pumps Market analysis: During the forecast period of 2022 to 2030, sales of breast pumps are anticipated to increase at a CAGR of 4.6% and reach a market valuation of US$ 2.45 Bn by the end of 2030, up from US$ 1.72 Bn in 2022.
Digital Breast Tomosynthesis (DBT) Equipment Market Sales: The global digital breast tomosynthesis (DBT) equipment market is expected to enjoy a valuation of US$ 2.3 Billion in the year 2022, and further expand at a CAGR rate of 14.1% to reach a valuation of ~US$ 8.4 Billion by the year 2032.
Breast Lesion Localization Device Market Outlook: The global demand for breast lesion localization devices market is set to grow by 5.5% from 2022 to 2032, with an estimated market value of around US$ 325.5 Million as of 2022.
Ultrasound-Guided Breast Biopsy Market Volume: The global ultrasound-guided breast biopsy market is expected to reach US$ 1,090 Mn in 2032, exhibiting a CAGR of 8% during the forecast period. Ultrasound-guided biopsy market is currently valued at US$ 720 Mn in 2022.
Automated Breast Ultrasound Systems Market Application: The automated breast ultrasound systems market is estimated to capture a valuation of US$ 1.95 billion in 2023 and is projected to reach US$ 7.23 billion by 2033. The market is estimated to secure a CAGR of 14% by 2033.
About Future Market Insights (FMI):
Future Market Insights, Inc. (ESOMAR certified, Stevie Award - recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10 years.
Contact Us:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
LinkedIn | Twitter | Blogs | YouTube
For Sales Enquiries: sales@futuremarketinsights.com
